HALO News and Press, Halozyme Therapeutics Inc. From 08/16/22

Halozyme Therapeutics ( NASDAQ: HALO ) has priced upsized offering of $625M of 1.00% convertible senior unsecured notes due  August 15, 2028. The offering was upsized from an originally announced $500M. Initial purchasers granted an option to purchase up...

Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028 PR Newswire SAN DIEGO , Aug. 15, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"...

Halozyme Therapeutics ( NASDAQ: HALO ) has announced a proposed offering of $500M of convertible senior notes due 2028. The notes are to be offered and sold to "qualified institutional buyers." They will accrue interest payable semi-annually in arrears and will mature on Aug...

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028 PR Newswire The Company plans to purchase up to $200 million worth of shares concurrently with, or shortly after, the pricing of the offering SAN ...

Halozyme Therapeutics, Inc. (HALO) Q2 2022 Earnings Conference Call August 09, 2022 04:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communication Helen Torley - President & Chief Executive Officer Nicole LaBrosse...

Halozyme ( NASDAQ: HALO ) stock gained 8.5% to $47.00 in Tuesday postmarket trading, after the company reported a rise in Q2 revenue, helped in part by a recent acquisition, and raised its FY 2022 guidance. San Diego, Calif.-based HALO develops drug delivery systems. Its...

Halozyme Therapeutics press release ( NASDAQ: HALO ): Q2 Non-GAAP EPS of $0.53. Revenue of $152.37M. Financial Outlook for 2022 The Company is raising its financial guidance for 2022 which was last provided on May 10, 2022, as a result of the recent close of the An...

HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS PR Newswire Closed Antares Pharma Acquisition, Accelerating High Growth Drug Delivery Leadership and Projected to be Accretive to Revenue for Full Year 2022 Second Quarter Revenue Increased 12...

Today, we take a look at Halozyme Therapeutics for the first time in many years. The company has a fairly unique business model within the healthcare space and is delivering consistent growth. An investment analysis follows in the paragraphs below. Evil is a choice o...

Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer PR Newswire Subcutaneous formulation with ENHANZE ® reduced treatment time to 3-8 minutes...